Tumor necrosis factor (TNF-a) is a proinflammatory cytokine that plays a critical role in the pathogenesis of inflammatory bowel disease. TNF-a causes an increase in intestinal permeability; however, the signaling pathways and the molecular mechanisms involved remain unclear. The major purpose of this study was to investigate the role of MAP kinase pathways (ERK1/2 and p38 kinase) and the molecular processes involved. An in vitro intestinal epithelial model system consisting of Caco-2 monolayers and an in vivo mouse model system were used to delineate the cellular and molecular mechanisms involved in TNF-a effects on tight junction barrier. The TNF-aeinduced increase in Caco-2 tight junction permeability was mediated by activation of the ERK1/2 signaling pathway, but not the p38 kinase pathway. Activation of the ERK1/2 pathway led to phosphorylation and activation of the ETS domain-containing transcription factor Elk-1. The activated Elk-1 translocated to the nucleus, where it bound to its binding motif on the myosin light chain kinase (MLCK) promoter region, leading to the activation of MLCK promoter activity and gene transcription. In addition, in vivo intestinal perfusion studies also indicated that the TNF-aeinduced increase in mouse intestinal permeability requires ERK1/2-dependent activation of Elk-1. These studies provide novel insight into the cellular and molecular processes that regulate the TNF-aeinduced increase in intestinal epithelial tight junction permeability. (Am J Pathol 2013 http://dx
Defective intestinal epithelial tight junction (TJ) barrier characterized by an increase in intestinal permeability is an important pathogenic factor contributing to the development of intestinal inflammation. 1e3 In various inflammatory diseases of the gut, including Crohn's disease, ulcerative colitis, celiac disease, and a number of infectious diarrheal syndromes, the disturbance in the intestinal TJ barrier allows increased antigenic penetration, contributing to the intestinal inflammatory response. 3e5 Tumor necrosis factor (TNF-a) is an essential mediator of inflammation in the gut. 6, 7 TNF-a levels are markedly elevated in patients with inflammatory conditions of the gut. 8, 9 It is well established that TNF-a causes an increase in intestinal TJ permeability in vivo and in vitro, which allows increased intestinal permeation of luminal antigens. 10e12 Animal studies have shown that enhancement of the intestinal TJ barrier prevents cytokine-mediated development of intestinal inflammation and diarrhea. 13, 14 Clinical studies have shown that antie TNF-a therapy leads to a retightening of the intestinal barrier and that the normalization of intestinal permeability is associated with long-term clinical remission. 7 In this regard, understanding the intracellular pathways and molecular mechanisms that mediate the TNF-aeinduced increase in intestinal permeability is important for identifying potential therapeutic targets and developing therapeutic strategies to prevent disturbance of the intestinal TJ barrier and consequent antigenic penetration.
Previous studies from our research group and others have shown that TNF-a causes an increase intestinal epithelial TJ permeability 6,15e18 and indicated that myosin light chain kinase (MLCK) plays a central role in the TNF-aeinduced increase in intestinal permeability. 6 ,17e19 TNF-a caused an increase in intestinal expression of MLCK, and inhibition of MLCK protein synthesis or MLCK activity prevented the TNF-aeinduced increase in intestinal permeability. Furthermore, the increase in MLCK protein expression was directly related to up-regulation of MLCK gene activity and increase in mRNA transcription. 6, 19 The targeted inhibition of MLCK and preservation of intestinal TJ barrier also resulted in inhibition of intestinal inflammation in various animal models of intestinal inflammation. 20, 21 However, the intracellular signaling pathways and the precise molecular mechanisms that mediate TNF-aeinduced activation of the MLCK gene and subsequent increase in intestinal permeability remain unclear. Mitogen-activated protein kinases (MAPK), including extracellular regulated protein kinase 1/ 2 (ERK1/2) and p38 kinase, have been suggested to play an important role in mediating proinflammatory actions of TNF-a, including cell growth, differentiation, stress, and inflammatory responses. 22e25 We hypothesized that TNF-a modulation of intestinal epithelial TJ permeability is mediated by MAPK pathway regulation of MLCK.
The major aims of the present studies were to investigate the intracellular signaling pathways and the molecular mechanisms that regulate TNF-a modulation of intestinal TJ permeability. We used both in vitro (filter-grown Caco-2 monolayers) and in vivo (live mouse intestinal perfusion) model systems to assess the intracellular and molecular mechanisms involved and to validate the in vivo relevance of the signaling and molecular pathways. We tested the hypothesis that the ERK1/2 or p38 kinase signaling pathway plays a key regulatory role in TNF-aeinduced activation of MLCK and the subsequent increase in intestinal epithelial permeability. Our data suggest that the TNF-aeinduced increase in intestinal TJ permeability is mediated by activation of the ERK1/2 signaling pathway, but not the p38 kinase pathway. Our data also suggest that ERK1/2 activation of nuclear transcription factor Elk-1 regulates MLCK gene activity by binding to the serum response element on the MLCK promoter region.
Materials and Methods

Chemicals
Cell culture media (Dulbecco's modified Eagle's medium), trypsin, fetal bovine serum, and related reagents were purchased from Life Technologies (Carlsbad, CA), as were glutamine, penicillin, streptomycin, and PBS. AntieERK1/2 (extracellular signal-regulated kinase 1/2), p-ERK1/2, Elk-1 (Ets-like gene 1), and p-Elk-1 antibodies were purchased from Abcam (Cambridge, MA). MLCK and antieb-actin antibodies were purchased from Sigma-Aldrich (St. Louis, MO). Horseradish peroxidaseeconjugated secondary antibodies for Western blot analysis were purchased from Life Technologies and Abcam (Cambridge, MA). siRNA of ERK1/2 and Elk-1 and transfection reagents were purchased from Dharmacon (Thermo Scientific, Pittsburgh, PA). The ERK1/2 inhibitor PD 98059 was purchased from Sigma-Aldrich. All other chemicals were purchased from Sigma-Aldrich, VWR International (West Chester, PA), Life Technologies, or Fisher Scientific.
Cell Cultures
Caco-2 cells (passage 18 to 26) purchased from the ATCC (Manassas, VA) were maintained at 37 C in a 5% CO 2 -enriched atmosphere, and they were kept in a culture medium composed of Dulbecco's modified Eagle's medium with 4.5 mg/mL glucose, 50 U/mL penicillin, 50 U/mL streptomycin, 4 mmol/L glutamine, 25 mmol/L HEPES, and 10% fetal bovine serum.
Determination of Epithelial Monolayer Resistance and Paracellular Permeability
An epithelial voltohmmeter (World Precision Instruments, Sarasota, FL) was used for measurement of the transepithelial electrical resistance (TER) of filter-grown Caco-2 intestinal monolayers, as previously reported. 26, 27 The effect of TNF-a on Caco-2 paracellular permeability was determined using an established paracellular marker, inulin, with a molar mass of 5000 g/mol. 26, 28 For transepithelial and permeability studies, Caco-2eplated filters having TER of 400 to 500 U,cm 2 were used. A known concentration (2 mmol/L) of radiolabeled inulin ( 14 C) was added to the apical solution.
Assessment of Protein Expression by Western Blot Analysis
Caco-2 monolayers were treated with 10 ng/mL TNF-a for varying time periods. At the end of the experimental period, Caco-2 monolayers were immediately rinsed with ice-cold PBS, and cells were lysed with lysis buffer [50 mmol/L Tris,HCl (pH 7.5), 150 mmol/L NaCl, 500 mmol/L NaF, 2 mmol/L EDTA, 100 mmol/L vanadate, 100 mmol/L phenylmethylsulfonyl fluoride, 1 mg/mL leupeptin, 1 mg/mL pepstatin A, 40 mmol/L paranitrophenyl phosphate, 1 mg/ mL aprotinin, and 1% Triton X-100) and scraped, and the cell lysates were placed in microcentrifuge tubes. Cell lysates were centrifuged to yield a clear lysate. Supernatant was collected, and protein measurement was performed using a Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA). Laemmli gel loading buffer was added to the lysate containing 20 mg of protein and boiled for 7 minutes, after which proteins were separated on SDS-PAGE gel. Proteins from the gel were transferred to a nitrocellulose membrane (Bio-Rad Laboratories) overnight. The membrane was incubated for 2 hours in blocking solution (5% nonfat dried milk in Tris-buffered salineeTween 20 buffer). The membrane was incubated with appropriate primary antibodies in blocking solution. Primary antibodies were used in concentrations according to the manufacturer's recommendations (usually 1 to 2 mg/mL). After being washed in Tris-buffered salinee1% Tween buffer, the membrane was incubated in appropriate secondary antibodies (1:2000) . After a washing in Tris-buffered salinee1% Tween 20 buffer, the membrane was developed using Luminol Western blotting reagents (Santa 
RNA Isolation and Reverse Transcription
Caco-2 cells (5 Â 10 5 /filter) were seeded into six-well Transwell permeable inserts (Corning Life Sciences, Tewksbury, MA) and grown to confluency. Filter-grown Caco-2 cells were then treated with the appropriate experimental reagents for the desired time periods. At the end of the experimental period, cells were washed twice with ice-cold PBS. Total RNA was isolated using an RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Total RNA concentration was determined by absorbance at 260/280 nm using a SpectraMax 190 microplate reader (Molecular Devices, Sunnyvale, CA). The reverse transcription was performed using an Applied Biosystems GeneAmp Gold RNA PCR core kit (Life Technologies). From each sample, 2 mg of total RNA was reverse-transcribed into cDNA in a 40-mL reaction containing 1Â RT-PCR buffer, 2. 
qPCR Quantification of Gene Expression
Quantitative real-time PCR (qPCR) was performed using an ABI Prism 7900 sequence detection system and a TaqMan universal PCR master mix kit (Life Technologies), as described previously. Each qPCR reaction contained 10 mL of reverse-transcriptase reaction mix, 25 mL of 2Â TaqMan universal PCR master mix, 0.2 mmol/L probe, and 0.6 mmol/L primers. Primer and probe design for the qPCR was performed using Applied Biosystems Primer Express software version 2 (Life Technologies). The following primers were used: MLCK-specific primers, forward 5 0 -AGGAA-GGCAGCATTGAGGTTT-3 0 and reverse 5 0 -GCTTTCAG-CAGGCAGAGGTAA-3 0 ; MLCK-specific probe, FAM 5 0 -TGAAGATGCTGGCTCC-3 0 TAMRA; internal control GAPDH-specific primers, forward 5 0 -CCACCCATGGCA-AATTCC-3 0 and reverse 5 0 -TGGGATTTCCATTGATGA-CCAG-3 0 ; and GAPDH-specific probe, JOE 5 0 -TGGCA-CCGTCAAGGCTGAGAACG-3 0 TAMRA. All runs were performed according to the default PCR protocol (50 C for 2 minutes and 95 C for 10 minutes, followed by 40 cycles of 95 C for 15 seconds, and then 60 C for 1 minute). For each sample, qPCR reactions were performed in triplicate, and the average C T was calculated. A standard curve was generated to convert the C T to copy numbers. Expression of MLCK mRNA was normalized with GAPDH mRNA expression. The average copy number of MLCK mRNA expression in control samples was set to 1.0. The relative expression of MLCK mRNA in treated samples was determined as a fold increase, relative to control samples.
siRNA of ERK1/2 and Elk-1
Targeted siRNAs were purchased from Dharmacon (Thermo Scientific). Caco-2 monolayers were transiently transfected using DharmaFECT transfection reagent (Thermo Scientific). In brief, 5 Â 10 5 cells/filter were seeded into a 12-well Transwell plate and grown to confluency. The Caco-2 monolayers were washed with PBS twice, and then 0.5 mL of Accell delivery medium (Thermo Scientific) was added to the apical compartment of each filter and 1.5 mL was added to the basolateral compartment of each filter. The siRNA of interest (5 ng) and DharmaFECT reagent (2 mL) were added to the apical compartment of each filter. The TNF-a experiments were performed at 96 hours after transfection. The efficiency of silencing was confirmed by Western blot analysis.
ELISA-Based Determination of in Vitro ERK1/2 Kinase Activity
For ELISA, biotinylated myelin basic protein (MBP) was diluted in PBS and incubated on streptavidin-coated 96-well plates at 37 C for 1 hour. The plates were washed three times with PBS, incubated with blocking solution (1 mg/mL bovine serum albumin in PBS) at 37 C for 1 hour, and then washed three more times with PBS. Ninety microliters of kinase reaction buffer [20 mmol/L Tris/HCl (pH 7.5), 10 mmol/L MgCl 2 , 50 mmol/L NaCl, 1 mmol/L dithiothreitol, 1 mmol/L NaF, 50 mmol/L ATP] provided by the manufacturer (MBL International, Woburn, MA) and 10 mL of samples containing immunoprecipitated ERK1/2 were added to each well, and the kinase reaction (phosphorylation of MBP) was performed at 37 C for 30 to 60 minutes. The reaction was stopped by removing the reaction mixtures and washing the plates three times with washing buffer [20 mmol/L Tris-HCl (pH 7.4), 0.5 mol/L NaCl, and 0.05% Tween 20] . The washed plates were incubated with 5 ng/mL antiep-MBP antibody at room temperature for 1 hour. The plates were washed four times with washing buffer, and goat anti-rabbit IgG antibody (diluted 1:2000 in washing buffer) was added to the wells, and the plates were incubated at 37 C for 1 hour. The plates were washed four more times and incubated with 100 mL of substrate solution tetramethylbenzidine at 37 C for 5 to 15 minutes. To stop the reaction, 100 mL of stop solution containing 0.5 N H 2 SO 4 was added. The absorbance at 450 nm was determined using a SpectraMax 190 microplate reader (Molecular Devices).
Nuclear Extracts and ELISA for Transcription Factor Activation
Filter-grown Caco-2 monolayers were treated with 10 ng/ mL TNF-a for 30 minutes. The Caco-2 monolayers were washed with ice-cold PBS, scraped, collected, and centrifuged at 20,817 Â g for 30 seconds. The cell pellets were TNF-a, TJ Barrier, and ERK1/2 Signaling
The American Journal of Pathology -ajp.amjpathol.orgresuspended in 200 mL of buffer A [10 mmol/L HEPES-KOH, 1.5 mmol/L MgCl 2 , 10 mmol/L KCl, 0.5 mmol/L dithiothreitol, and 0.2 phenylmethylsulfonyl fluoride (pH 7.9)] and incubated on ice for 15 minutes. After centrifugation at 14,000 rpm for 30 seconds, pelleted nuclei were resuspended in 30 mL of buffer C [20 mmol/L HEPES-KOH (25% glycerol), 420 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 0.2 mmol/L EDTA, 0.5 mmol/L dithiothreitol, and 0.2 mmol/L phenylmethylsulfonyl fluoride (pH 7.9)]. After incubation on ice for 20 minutes, the lysates were centrifuged at 14,000 rpm for 20 minutes. Protein concentrations were determined using the Bradford method. The Elk-1 DNA-binding assay was performed using TransAM ELISA-based kits from Active Motif (Carlsbad, CA) according to the manufacturer's protocol. In brief, the binding reactions contained 1 pmol/L biotinylated probe (Integrated DNA Technologies, Coralville, IA) and 5 mg of nuclear extract in complete binding buffer with a total volume of 50 mL. After 30 minutes of incubation, the solution was transferred to an individual well on 96-well plate and incubated for 1 hour. The appropriate antibody (2 mg/mL) was added to the well to bind the target protein in nuclear extract. After incubation for 1 hour, the antibody was removed, and 100 mL of horseradish peroxidaseeconjugated secondary antibody was added to the well and incubated for 1 hour. Subsequently, 100 mL of developing solution was added for 2 to 10 minutes, and then 100 mL of stop solution was added. The absorbance at 450 nm was determined using a SpectraMax 190 microplate reader (Molecular Devices).
Cloning of the Full-Length MLCK Promoter Region and Deletion Constructs
The MLCK promoter region was cloned using a GenomeWalker system (Clontech Laboratories, Mountain View, CA). A 2091-bp DNA fragment (À2109 to À18) was amplified by PCR. The amplification condition was 94 C for 2 minutes, followed by 43 cycles at 94 C for 1 minute, 50 C for 1 minute, and 72 C for 2 minutes, and then 72 C for 5 minutes. The resultant PCR product was digested with HindIII and KpnI and inserted into pGL3-basic luciferase reporter vector (Promega, Madison, WI). The sequence was confirmed at the University of New Mexico DNA Research Services. Construction of MLCK promoter reporter plasmids was performed using the pGL3-basic luciferase reporter vector. Deletions of MLCK promoter were performed according to the PCR method. The PCR conditions were 94 C for 2 minutes, followed by 43 cycles at 94 C for 1 minute, 50 C for 1 minute, and 72 C for 2 minutes, and then 72 C for 5 minutes. The resultant PCR products were cloned into pGL3-basic luciferase reporter vector and the sequences were confirmed.
Transfection of DNA Constructs and Assessment of Promoter Activity
DNA constructs of MLCK promoters were transiently transfected into Caco-2 cells using Lipofectamine 2000 transfection reagent (Life Technologies). Renilla luciferase vector (pRL-TK; Promega) was cotransfected with each plasmid construct, as an internal control. Cells (5 Â 10 5 per filter) were seeded into a six-well Transwell plate and grown to confluency. The Caco-2 monolayers were washed with PBS twice, and then 1.0 mL of Opti-MEM medium was added to the apical compartment of each filter and 1.5 mL was added to the basolateral compartment of each filter. One microgram of each plasmid construct and 0.25 mg of pRL-TK or 2 mL of Lipofectamine 2000 (Life Technologies) were preincubated in 250 mL of Opti-MEM medium. After 5 minutes of incubation, the two solutions were mixed and incubated for another 20 minutes, and the mixture was added to the apical compartment of each filter. After incubation for 3 hours at 37 C, 500 mL of Dulbecco's modified Eagle's medium containing 10% fetal bovine serum were added to both sides of the filter to reach a 2.5% final concentration of fetal bovine serum. Subsequently, the medium was replaced with normal Caco-2 growth medium at 16 hours after transfection.
Specific experiments were performed at 48 hours after transfection. At the completion of specific experimental treatments, Caco-2 cells were washed twice with 1 mL of ice-cold PBS, and 400 mL of 1Â passive lysis buffer was added; cells were then incubated at room temperature for 15 minutes, scraped, transferred into an Eppendorf tube, and centrifuged for 15 seconds at 13,000 rpm in a microcentrifuge. Luciferase activity was determined using a dual luciferase assay kit (Promega). Twenty microliters of the supernatant was used for each assay. Luciferase values were determined using a Lumat LB 9507 luminometer (Berthold Technologies, Oak Ridge, TN; Bad Wildbad, Germany). The value of reporter luciferase activities were then divided by that of Renilla luciferase activities to normalize for differences in transfection efficiencies. The average activity value of the control samples was set to 1.0. The luciferase activity of MLCK promoter in treated samples was determined relative to control samples.
Site-Directed Mutagenesis
Mutagenesis of MLCK promoter was performed using an Invitrogen GeneTailor site-directed mutagenesis system (Life Technologies). In brief, primers were generated that included the mutation site flanked by a wild-type sequence on either side (mutant primer, forward 5 0 -CTGCAGGAAG-GCAGCTCCCACAATTCCTTCTTTCTACCCCTGCCA-3 0 and reverse 5 0 -TGGGAGCTGCCTTCCTGCAGGTGAAA-GGCA-3 0 ). A PCR reaction produced a new complete copy of the plasmid containing the mutation coded for by the primers. The linear PCR product was subsequently transformed into DH5-T1 Escherichia coli, which circularized the PCR product and digested any remaining parent plasmid. DNA sequence was then verified at the University of New Mexico DNA Research Services. After the experimental period, mice were anesthetized with isoflurane. After midline incision of the abdomen, 5 cm of intestine segment was isolated and cannulated at the proximal and distal ends with polyethylene tubing (0.76 mm internal diameter). Flushing solution [140 mmol/L NaCl, 10 mmol/L HEPES (pH 7.4)] warmed to 37 C was first perfused through the intestine at 1 mL/minute for 20 minutes, followed by air flush to remove residual contents using an external pump (Bio-Rad Laboratories). This was followed by perfusion of 5 mL of perfusate solution [85 mmol/L NaCl, 10 mmol/L HEPES, 20 mmol/L sodium ferrocyanide, 5 mmol/L KCl, 5 mmol/L CaCl 2 (pH 7.4)] containing Texas Redelabeled dextran 10K (10 kDa) in a recirculating manner at 0.75 mL/minute for 2 hours. The abdominal cavity was covered with moistened gauze, and body temperature was measured via rectal thermometer; body temperature was maintained at 37.5 AE 0.5 C using a heating lamp. Aliquots (1 mL) of test solution were removed at the beginning and end of the perfusion. After perfusion, the animal was sacrificed, the perfused intestine segment was excised, and the length was measured. The excised intestinal loop was then snap-frozen in optimal cutting temperature compound or was used for protein and RNA analysis. Ferrocyanide concentration in the perfusate was measured using a colorimetric assay. Texas Redelabeled dextran 10K concentration was measured using an excitation wavelength of 595 nm and an emission wavelength of 615 nm in a microplate reader.
Probe clearance was calculated as
where C is the probe concentration and V is the perfusate volume; the subscripts i, f, and avg indicate initial measured, final, and average values; T is perfusion time in hours; and L is the length of the perfused intestine section in centimeters. V f was calculated as
Animal Surgery and in Vivo Transfection of ERK1/2 and Elk-1 siRNA Mice were fasted for 24 hours before the surgery. Mice were anesthetized with isoflurane (4% for surgical induction and 1% for maintenance) using oxygen as carrier during surgical procedures. Surgical procedures were performed using sterile technique. The abdomen was opened by a midline incision, and a 6-cm segment of intestine was isolated at the proximal and distal ends and tied with sutures. Next, 0.5 mL of siRNA transfection solution (containing Accell medium, 2.5 nmol ERK1/2 or Elk-1 siRNA, and 50 mL of Lipofectamine 2000 transfection reagent) was introduced into the lumen of the isolated intestinal segment using a 30-G needle for a 1-hour transfection period. Control animals underwent sham surgery, for which the siRNA transfection solution contained Accell medium, 2.5 nmol nontarget siRNA, and 50 mL of Lipofectamine 2000 transfection reagent. The abdominal cavity was covered with moistened gauze. Body temperature was monitored continuously with a rectal probe and was maintained at 37.5 AE 0.5 C using a heating pad. After the 1-hour transfection period, each end of the intestinal segment was untied, the intestine was placed back into the abdominal cavity, and the abdomen was closed. At 3 days after transfection, functional studies of intestinal epithelial barrier were performed. The surgery and the in vivo transfection procedures had no effect on food intake or body weight of the animals during the experimental period. Animal weight averaged between 23 and 25 g during the experimental period.
Statistical Analysis
Statistical significance of differences between mean values was assessed with Student's t-tests for unpaired data and analysis of variance analysis whenever required. All reported significance levels represent two-tailed P values. A P value of <0.05 was used to indicate statistical significance. Each experiment was performed in triplicate or quadruplicate (n Z 3 or 4), and all experiments were repeated at least three times to ensure reproducibility. TNF-a (10 ng/mL) causes a time-dependent increase in Caco-2 ERK1/2 phosphorylation; total ERK1/2 was used for equal protein loading. B: TNF-a causes a time-dependent increase in ERK1/2 activity as determined by ELISA-based in vitro kinase activity using MBP as the substrate. Data are expressed as means AE SEM. n Z 4. *P < 0.001 versus control.
Results
The TNF-aeInduced Increase in Caco-2 TJ Permeability Is Regulated by MAP Kinase Activation
We examined the possibility that the TNF-aeinduced increase in Caco-2 TJ permeability is mediated by MAP kinase activation. Because TNF-a has been shown to activate MAP kinases ERK1/2 and p38 kinase in various cell types, 24, 25 these two kinase pathways were targeted. The time-course effect of 10 ng/mL TNF-a on ERK1/2 or p38 kinase activation was determined by measuring ERK1/2 phosphorylation in filter-grown Caco-2 monolayers. TNF-a caused a rapid increase in ERK1/2 phosphorylation in Caco-2 cells, starting at about 10 minutes and continuing up to 60 minutes, as determined by p-ERK1/2 immunoblotting ( Figure 1A) . In contrast, TNF-a did not have a significant effect on p38 kinase phosphorylation (Supplemental Figure S1 ). The total ERK1/2 level was not affected by the TNF-a treatment ( Figure 1A ). The effect of TNF-a on ERK1/2 kinase activity was also confirmed by an ELISA-based in vitro kinase assay. The kinase activity of immunoprecipitated ERK1/2 was directly measured in vitro using MBP as the substrate. TNF-a caused a rapid increase in Caco-2 ERK1/2 kinase activity, starting at about 5 to 10 minutes ( Figure 1B ). These data suggested that TNF-a causes a rapid activation (within minutes) of ERK1/2 (but not p38 kinase) in Caco-2 monolayers.
To determine the requirement of ERK1/2 activation in the TNF-aeinduced increase in Caco-2 TJ permeability, the effect of ERK1/2 inhibition was examined. Caco-2 TJ permeability was determined by measuring Caco-2 TER or transepithelial flux of the paracellular marker inulin. 26, 28 TNF-a caused a time-dependent decrease in Caco-2 TER and an increase in transepithelial flux of inulin (Figure 2, A  and B) . At 100 mmol/L, the ERK1/2 inhibitor PD 98059 inhibited TNF-aeinduced activation of ERK1/2, as assessed by in vitro kinase activity ( Figure 2C) , and prevented the decrease in TER ( Figure 2D ) and increase in inulin flux ( Figure 2E ). In contrast, the p38 kinase inhibitor SB 203580 did not have any effect on the TNF-aeinduced increase in Caco-2 TJ permeability (Supplemental Figure S2) . These results suggested that ERK1/2 activation is required for the TNF-aeinduced increase in Caco-2 TJ permeability.
To further confirm the requirement of ERK1/2 for the effect of TNF-a on Caco-2 TJ permeability, ERK1/2 expression was selectively knocked down by siRNA transfection. Transfection of ERK1/2 siRNA caused a nearcomplete depletion of ERK1/2 in filter-grown Caco-2 Figure 3A) . The siRNA-induced knockdown of ERK1/2 prevented the TNF-aeinduced decrease in Caco-2 TER ( Figure 3B ) and increase in inulin flux ( Figure 3C ), confirming the requirement of ERK1/2 in the TNF-aeinduced increase in Caco-2 TJ permeability.
ERK1/2 Signaling Pathway Is Involved in the Regulation of MLCK Gene and Protein Expression
Previous studies from our research group and others have shown that the TNF-aeinduced increase in Caco-2 TJ permeability is mediated by an increase in MLCK protein expression and activity. 6,17e19 However, the intracellular signaling pathways or the molecular mechanisms involved in the TNF-a regulation of MLCK gene and protein expression remain unclear. In the present study, we examined the involvement of the ERK1/2 signaling pathway in TNF-a upregulation of MLCK gene and protein expression. TNF-a caused an increase in Caco-2 MLCK mRNA and protein expression ( Transcription Factor Elk-1 Regulates MLCK Gene Activity and TJ Permeability Next, we examined the nuclear transcription factor and the molecular determinants that regulate the TNF-aeinduced increase in MLCK gene activity and Caco-2 TJ permeability. Nuclear transcription factor Elk-1, a direct substrate of ERK1/2, binds to serum response element on a promoter region and regulates gene transcription.
32e34 Using PromoterInspector software (Genomatix, Munich, Germany), we identified two Elk-1 binding motifs or serum response elements on the MLCK promoter region. The effect of TNFa on Elk-1 activation was examined by measuring Elk-1 phosphorylation and by ELISA-based DNA binding assay. TNF-a caused a time-dependent increase in Caco-2 Elk-1 phosphorylation (Ser383) ( Figure 5A ). TNF-a also caused an increase in binding of activated Elk-1 (in the nuclear fraction) to the Elk-1 binding sequence on the DNA probe ( Figure 5B ). The ERK1/2 inhibitor PD 98059 inhibited the TNF-aeinduced increase in Elk-1 phosphorylation and the DNA binding of Elk-1 ( Figure 5, C and D) .
We then examined the regulatory role of Elk-1 on MLCK promoter activity, using siRNA silencing of Elk-1 in Caco-2 monolayers. The transfection of filter-grown Caco-2 monolayers with Elk-1 siRNA caused a near-complete depletion of Elk-1 expression ( Figure 6A ). TNF-a caused an increase in MLCK promoter activity, and siRNA knockdown of Elk-1 prevented the increase in MLCK promoter activity ( Figure 6B ). siRNA knockdown of Elk-1 also inhibited the TNF-aeinduced increase in MLCK at the mRNA and protein levels ( Figure 6 , C and D) and the increase in Caco-2 TJ permeability ( Figure 6, E and F) . Taken together, these data suggested that Elk-1 activation is required for the increase in MLCK gene activity and the subsequent increase in Caco-2 TJ permeability.
Elk-1 Regulation of MLCK Promoter
Next, we determined the molecular determinants that mediate the TNF-a modulation of MLCK promoter activity. As noted above, two serum response elements or Elk-1 binding sequences were identified on the MLCK promoter region: site A, between À1118 and À1102 (5 0 -TGGCCTTCCTCCCTC-3 0 ), 
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The American Journal of Pathology -ajp.amjpathol.organd site B, between À310 and À296 (5 0 -GAAAATGGAA-GTCCAAG-3 0 ) ( Figure 7A ). Three MLCK promoter deletion constructs were generated that contained both Elk-1 binding motifs a and b (full-length promoter region) and DNA constructs that contained only the downstream binding site B.
Two deletion constructs encoding the site B were generated: MLCK À926, which encodes the promoter region upstream of the binding sequence B (À310 to À296) and MLCK À313, which encodes the sequence B but does not encode the upstream promoter region beyond À313. TNF-a treatment produced a similar proportional increase in all three DNA constructs ( Figure 7 , B and C), suggesting that the presence of the binding site B alone was sufficient to cause an increase in MLCK promoter activity and that site A is not required. To validate the requirement of site B in the regulation of MLCK promoter activity, binding site B was mutated via site-directed mutagenesis. The mutation of site B inhibited the TNF-aeinduced increase in promoter activity ( Figure 8A ), confirming that site B was necessary for the up-regulation of promoter activity. Lastly, the effect of siRNA-induced silencing of Elk-1 on the TNF-aeinduced increase in MLCK promoter activity in MLCK À313 was determined. The siRNA-induced knockdown of Elk-1 inhibited the TNF-aeinduced increase in promoter activity in MLCK À313 ( Figure 8B ). Taken together, these data indicated that Elk-1 binding site B located within the minimal promoter region is the regulatory site responsible for TNF-aeinduced activation of MLCK promoter activity.
The Role of ERK1/2 and Elk-1 in the TNF-aeInduced Increase in Mouse Intestinal Permeability in Vivo
To this point, our studies suggested that ERK1/2 signaling cascade activation is required for the TNF-a modulation of MLCK and TJ permeability in filter-grown Caco-2 monolayers; however, the in vivo relevance of these findings remained unclear. We therefore examined the involvement of the ERK1/2 signaling pathway in TNF-a modulation of mouse intestinal permeability by recycling intestinal perfusion of mouse small intestine in vivo. 31 Intraperitoneal injection of 5 mg of TNF-a caused an increase in intestinal permeability, as assessed by mucosal-to-serosal flux of a commonly used paracellular marker, Texas Rededextran 10K ( Figure 9A ). TNF-a treatment resulted in a timedependent increase in ERK1/2 phosphorylation and activation in the small intestinal tissue (Figure 9 , B and C). TNF-a also caused an increase in intestinal MLCK mRNA and protein expression (Figure 9, D and E) . To confirm the regulatory role of the ERK1/2 pathway in intestinal MLCK expression and intestinal permeability in vivo, intestinal ERK1/2 expression was silenced by in vivo siRNA transfection of small intestine, using a recently described in vivo transfection methodology. 29, 31 In brief, 6 cm of mouse jejunum was isolated using sutures, and the mucosal surface was exposed to transfection solution containing ERK1/2 siRNA for 1 hour; the sutures were then removed, the intestinal segment was reinserted into the original location in the abdomen, and the abdominal cavity was closed with sutures. After 2 days, to allow for ERK1/2 depletion, mice were treated with TNF-a; intestinal permeability studies were performed on day 3. In vivo ERK1/2 siRNA transfection resulted in a near-complete knockdown of ERK1/2 in the intestinal tissue ( Figure 10A ). The in vivo siRNA knockdown of ERK1/2 prevented the TNF-aeinduced increase in intestinal MLCK expression ( Figure 10B ) and increase in intestinal permeability ( Figure 10C ). Taken together, these results suggest a regulatory role for the ERK1/2 kinase pathway in TNF-a modulation of intestinal MLCK expression and intestinal permeability in vivo.
Next, we examined the possible involvement of Elk-1 in TNF-a modulation of mouse intestinal permeability in vivo. TNF-a administration caused a time-dependent increase in Figure 6 A: Elk-1 siRNA transfection results in a near-complete depletion in Elk-1 protein expression in filter-grown Caco-2 monolayers. B: Elk-1 siRNA transfection significantly prevents the TNF-aeinduced increase in Caco-2 MLCK promoter activity. C: Elk-1 silencing by siRNA prevents the TNF-aeinduced increase in Caco-2 MLCK mRNA levels. D: Elk-1 silencing by siRNA transfection abolishes TNF-a up-regulation of Caco-2 MLCK protein expression. E: Elk-1 siRNA transfection prevents the TNF-aeinduced decrease in Caco-2 TER. F: Elk-1 silencing inhibits the TNF-aeinduced increase in mucosal-to-serosal inulin flux. Data are expressed as means AE SEM. n Z 4 (E); n Z 5 (B and F); n Z 8 (C). *P < 0.001, **P < 0.0001 versus control. 
TNF-a, TJ Barrier, and ERK1/2 Signaling
The American Journal of Pathology -ajp.amjpathol.orgintestinal tissue Elk-1 phosphorylation ( Figure 11A ). Timecourse studies indicated that TNF-aeinduced ERK1/2 activation ( Figure 9 , B and C) preceded Elk-1 activation. We also examined the effect of siRNA-induced silencing of Elk-1 on mouse small intestinal MLCK expression and mouse intestinal permeability. siRNA-induced knockdown of Elk-1 in vivo ( Figure 11B ) resulted in inhibition of the TNF-aeinduced increase in intestinal tissue MLCK protein expression and mouse intestinal permeability ( Figure 11 , B and C). siRNA-induced knockdown of ERK1/2 also inhibited the increase in Elk-1 phosphorylation, confirming that ERK1/2 activation is required for the intestinal tissue Elk-1 activation in vivo ( Figure 11D ). Taken together, these data suggested that the TNF-aeinduced increase in mouse intestinal permeability in vivo is also mediated by ERK1/2 activation of Elk-1 and by Elk-1edependent increase in MLCK expression.
Discussion
The intracellular signaling pathways that mediate TNF-a modulation of intestinal epithelial TJ barrier remain unclear. Previous studies from our research group and others indicated that the TNF-a modulation of intestinal TJ barrier is dependent on MLCK gene activation and protein expression. 6,17e19 With the present studies, we have extended our previous findings to delineate the intracellular signaling cascades that regulate the TNF-a modulation of intestinal permeability in vitro and in vivo.
The MAP kinase p38 and ERK1/2 pathways play an important role in mediating many of the TNF-aeinduced immune responses, 24, 25 and the ERK1/2 and p38 kinase pathways are involved in the regulation of growth, differentiation, apoptosis, and inflammatory responses. 25, 35 However, the involvement of MAP kinase pathways in TNF-a modulation of intestinal TJ permeability in vitro and in vivo had not been reported previously. We therefore investigated the possibility that MAP kinase pathways may play a regulatory role in the effect of TNF-a on intestinal TJ permeability. Our results indicate that TNF-a causes activation of ERK1/2, but not p38 kinase, and that targeted inhibition of ERK1/2 kinase activity (but not p38 kinase) prevents the TNF-aeinduced increase in Caco-2 TJ permeability, suggesting that the ERK1/2 signaling pathway (but not the These findings contradict recent data from our research group showing that IL-1b modulation of intestinal epithelial TJ barrier is dependent on both ERK1/2 and p38 kinase activation. 36, 37 Those studies indicated that IL-1b activation of the p38 kinase pathway is necessary for the IL1beinduced increase in Caco-2 TJ permeability, and inhibition of p38 kinase activity prevented the IL-1beinduced increase in Caco-2 TJ permeability. 36 In contrast to earlier results with IL-1b, in the present studies TNF-a did not cause an activation of p38 kinase in Caco-2 monolayers, and the p38 kinase inhibitor SB 203580 did not affect the TNF-aeinduced increase in Caco-2 TJ permeability. These results suggest that the effects of IL-1b and TNF-a on Caco-2 TJ barrier are regulated by distinct intracellular processes. Interestingly, the ERK1/2 signaling pathway has been shown to have different effects on intestinal epithelial TJ barrier. In studies using epidermal growth factor, ERK1/2 activation mediated the intestinal TJ barrier enhancement. 38 Similarly, probiotic enhancement of intestinal TJ barrier also required ERK1/2 activation. 39 In mice, bile-induced enhancement of intestinal barrier also involved ERK1/2 activation. 40 On the other hand, mycotoxin-induced and IL-1beinduced increases in intestinal epithelial TJ permeability require ERK1/2 activation. 37, 41 Thus, published data suggest that the ERK1/2 signaling pathway regulates both enhancement and attenuation of intestinal TJ barrier. How the ERK1/2 signaling pathway differentially regulates the intestinal TJ barrier requires further investigation.
Previous studies have shown that the TNF-aeinduced increase in Caco-2 TJ permeability is associated with an increase in MLCK gene and protein expression, and inhibition of MLCK expression or MLCK activity prevented the increase in Caco-2 TJ permeability. 6,17e19 In the present studies, we examined the regulatory role of the ERK1/2 signaling cascade in mediating TNF-a modulation of MLCK gene activity and protein expression. ERK1/2 inhibitor or gene silencing studies demonstrated the requirement of ERK1/2 activation in the TNF-aeinduced increase in MLCK gene activity and protein expression. As has been shown previously, 6, 19 the increase in MLCK expression and 
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The American Journal of Pathology -ajp.amjpathol.orgactivity was responsible for the TNF-aeinduced increase in Caco-2 TJ permeability. Presumably, the increase in MLCK activity leads to myosin light chain phosphorylation and myosin-Mg 2þ -ATPaseedependent opening of the intestinal TJ barrier. 42 As for the molecular mechanisms that regulate the MLCK gene activation and gene transcription, our studies suggest that the nuclear transcription factor Elk-1 is an important mediator of MLCK gene activity and Caco-2 TJ permeability. Elk-1 belongs to the ETS domain transcription factor family and the ternary complex factor subfamily and is a direct substrate of ERK1/2.
34,43e45 On activation, Elk-1 forms a ternary complex with the serum response factor protein and binds to the serum response element, inducing activation of the target gene. 34 Serine phosphorylation of Elk-1 (Ser383 and Ser389) is necessary for the transcriptional regulation. ERK1/2 is known to induce phosphorylation and activation of Elk-1. 33, 34, 46 Our present results show that TNF-a causes ERK1/2-dependent phosphorylation and activation of Elk-1. Moreover, inhibition of ERK1/2 activation or ERK1/2 knockdown prevented TNF-a activation of Elk-1, suggesting that Elk-1 activation is directly regulated by ERK1/2. Our results also showed that Elk-1 plays an essential role in TNF-a up-regulation of MLCK, and siRNA silencing of Elk-1 inhibited the increase in MLCK gene activity and mRNA transcription and also inhibited the increase in Caco-2 TJ permeability. Our promoter binding studies demonstrated binding of activated Elk-1 to the putative binding site (serum response element) on the MLCK promoter region, and sitedirected mutagenesis studies confirmed the requirement of the serum response element in TNF-a up-regulation of the promoter activity. Thus, our data suggest that binding of activated Elk-1 to the serum response element is important in the regulation of MLCK promoter activity. Taken together, our findings suggest that the ERK1/ 2 activation of Elk-1 leads to MLCK promoter activation and subsequent increase in MLCK mRNA transcription and translation and MLCK-dependent opening of the Caco-2 TJ barrier.
We also examined the in vivo mechanisms of TNF-a regulation of intestinal permeability, using recycling intestinal perfusion of isolated segment of mouse small intestine in vivo. In previous studies, intraperitoneal administration of TNF-a resulted in an increase in intestinal permeability to dextran 10K. 31 In the present studies, the increase in mouse intestinal permeability was associated with an increase in ERK1/2 activity, and intestinal tissueespecific silencing of ERK1/2 completely inhibited the TNF-aeinduced increase in mouse intestinal permeability, suggesting that the TNFaeinduced increase in intestinal permeability is regulated by the ERK1/2 signaling pathway. Our in vivo studies also indicated that TNF-a causes an ERK1/2-dependent activation of Elk-1 and that Elk-1 activation was required for the TNF-aeinduced increase in intestinal MLCK expression and intestinal permeability. These data suggest that a similar signaling mechanism regulates the effect of TNF-a on intestinal permeability both in vivo and in vitro. Our studies also suggest that in vivo targeting of ERK1/2 signaling pathways is effective in preventing the TNF-aeinduced increase in intestinal permeability. To our knowledge, this is the first study to show that the in vivo activation of the ERK1/2 signaling pathway regulates the TNF-aeinduced increase in intestinal permeability.
In conclusion, our results provide new insight into the intracellular signaling pathways and molecular processes that regulate TNF-a modulation of intestinal TJ permeability. The findings suggest that TNF-a causes a rapid activation of ERK1/2, which in turn leads to phosphorylation and activation of Elk-1; the activated Elk-1 binds to the serum response element on the MLCK promoter, leading to MLCK gene activation, transcription, protein expression, and MLCK-dependent opening of the intestinal TJ barrier.
Our in vivo studies also demonstrated the feasibility of therapeutic targeting of ERK1/2 and Elk-1 to prevent the TNF-aeinduced increase in intestinal TJ permeability in vivo. 
